Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

Breast Cancer Research and Treatment, published by Springer, stands as a pivotal journal within the domains of Cancer Research and Oncology, exemplified by its impressive Q2 and Q1 quartile rankings, respectively, in the 2023 category rankings. Since its inception in 1981, this journal has provided a vital platform for disseminating cutting-edge research focused on all aspects of breast cancer, ranging from molecular biology to treatment strategies. With an ISSN of 0167-6806 and E-ISSN of 1573-7217, it captures a broad audience of researchers, clinicians, and students dedicated to improving patient outcomes. The journal emphasizes high-quality, peer-reviewed studies that pave the way for advancements in therapy and direct novel insights into oncological practices. By maintaining a strong ranking in Scopus with percentile placements of 74th in Oncology and 61st in Cancer Research, Brest Cancer Research and Treatment continues to foster innovation and collaboration in the fight against breast cancer.

Lung Cancer - Targets and Therapy, published by Dove Medical Press Ltd, serves as a pivotal Open Access journal dedicated to advancing knowledge and research in the field of oncology, specifically focusing on lung cancer. Since its inception in 2010, this journal has provided a platform for disseminating high-quality research articles, reviews, and clinical studies, thereby enhancing the understanding of lung cancer mechanisms, therapies, and clinical outcomes. Currently ranked in the Q2 quartile within the oncology category and positioned at rank #80 out of 404 in Scopus, it resides in the 80th percentile of its field, reflecting its significant impact and relevance. With a commitment to promoting innovative therapies and strategies, Lung Cancer - Targets and Therapy is an essential resource for researchers, healthcare professionals, and students eager to contribute to the evolving landscape of cancer treatment and research.

The World Journal of Oncology, published by ELMER PRESS INC, is a vibrant platform for disseminating groundbreaking research and advancements in the field of oncology. With its ISSN 1920-4531 and E-ISSN 1920-454X, this journal is dedicated to publishing high-quality studies that enhance our understanding of cancer and its treatment. The journal is recognized for its significant contributions, evidenced by its Q2 classification in both Cancer Research and Oncology categories in 2023, and accolades such as a Scopus rank of #126/404 in Medicine _ Oncology. Catering to the needs of researchers, professionals, and students, the World Journal of Oncology offers an essential resource for the latest scientific insights and clinical practices, ensuring the global oncology community remains informed and engaged. The journal operates under a selective publication model, maintaining rigor in peer review while facilitating knowledge sharing across converged years from 2014 to 2016 and 2020 to 2024, further establishing its importance in the ongoing fight against cancer.

International Journal of Clinical and Experimental Pathology, published by E-CENTURY PUBLISHING CORP, serves as a vital resource for professionals in the field of pathology. With its ISSN 1936-2625, the journal has positioned itself within the competitive landscape of medical journals, achieving commendable rankings in Scopus, particularly in the categories of Pathology and Forensic Medicine (Rank #98/185) and Histology (Rank #38/58). Although its coverage in Scopus has been discontinued, the journal’s past contributions from 2009 to 2017 continue to be a touchstone for researchers interested in advancing their understanding of clinical and experimental pathology. The open-access format ensures accessibility to a wide audience, fostering collaboration and education in this essential medical discipline. By bridging clinical research and experimental findings, this journal plays a crucial role in disseminating knowledge and enhancing practices within pathology, making it an indispensable tool for researchers, professionals, and students alike.

Molecular Cancer, published by BMC, stands as a premier open access journal dedicated to advancing our understanding of cancer biology, treatment, and prevention since its inception in 2002. With an impressive Q1 ranking in the domains of Cancer Research, Molecular Medicine, and Oncology, this journal occupies a significant position in the academic landscape, emphasizing high-quality research that influences clinical practices and future studies. The journal is indexed in leading databases with exceptional Scopus ranks, reflecting its rigorous peer-review process and impactful contributions to the field, where it ranks in the top 2-3 positions across various relevant categories. Based in the United Kingdom, Molecular Cancer offers researchers worldwide a valuable platform for disseminating innovative findings that drive the biomedical community forward. The journal's open access model ensures that groundbreaking research is freely accessible, fostering collaboration and knowledge sharing among professionals, students, and academics alike. Explore cutting-edge developments in cancer research through Molecular Cancer and join a community committed to improving patient outcomes and advancing scientific discovery.

Cancer Research, published by the American Association for Cancer Research, is a premier journal in the field of oncology, renowned for its commitment to advancing cancer research since its inception in 1941. With an impressive impact factor reflecting its vital role in the field, this journal consistently ranks in the Q1 quartile for both Cancer Research and Oncology, positioning it among the top 7.5% of journals in these categories. The journal serves as a crucial platform for researchers, professionals, and students to disseminate and gain insights into groundbreaking studies that shape our understanding of cancer biology, prevention, diagnosis, and treatment. While it is not an open-access publication, its rigorous peer-review process ensures that only high-quality research is published, thus maintaining a standard of excellence in the scientific community. With a strong legacy and an ever-expanding influence, Cancer Research continues to be essential for anyone dedicated to the fight against cancer, showcasing cutting-edge research that drives scientific discovery and innovation.

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, published by Taylor & Francis AS, serves as a pivotal platform for facilitating advanced research and discourse in the fields of Genetics, Molecular Biology, Molecular Medicine, and Pathology. With an impressive Impact Factor and a distinguished status as Q2 in multiple categories, along with a prestigious Q1 ranking in Pathology and Forensic Medicine (2023), this journal continues to attract contributions from leading experts and budding researchers alike. The journal aims to address critical developments in molecular diagnostics, providing insightful reviews that propel the understanding and application of diagnostic techniques in various medical contexts. Accessible to a diverse audience in the academic community, the journal emphasizes the importance of molecular diagnostics in both clinical and laboratory settings, promoting innovative methodologies and comprehensive evaluations of emerging technologies. With ongoing convergence of scientific discovery advancing rapidly from 2001 through 2024, EXPERT REVIEW OF MOLECULAR DIAGNOSTICS remains essential for those committed to furthering the fields of molecular diagnostics and healthcare advancements globally.

Fetal and Pediatric Pathology, an esteemed journal published by TAYLOR & FRANCIS INC, is dedicated to advancing the field of pediatric and fetal medicine through the dissemination of high-quality research and clinical insights. With an ISSN of 1551-3815 and an E-ISSN of 1551-3823, the journal has been a key resource for researchers and practitioners since its inception in 1983. Based in the United Kingdom, it covers a broad spectrum of topics relevant to Medicine, Pathology and Forensic Medicine, and Pediatrics, Perinatology, and Child Health, consistently reflecting on contemporary challenges faced in these fields. The journal has attained a commendable Q3 ranking within its categories as of 2023, underlining its relevance in the academic community. Though not an open-access publication, the research presented in Fetal and Pediatric Pathology plays a pivotal role in informing practice, guiding future studies, and enhancing the understanding of diseases affecting fetuses and children. Its convergence of research throughout multiple years, continuing until 2024, marks it as a crucial platform for ongoing scientific dialogue and innovation, aimed at fostering better health outcomes for younger populations.

Annals of Diagnostic Pathology, published by Elsevier Science Inc, is a pivotal journal in the field of diagnostic pathology that has significantly contributed to the advancement of medical science since its inception in 1997. With an ISSN of 1092-9134 and E-ISSN of 1532-8198, this esteemed journal is positioned within the Q2 category in both Medicine (miscellaneous) and Pathology and Forensic Medicine, reflecting its high-quality research contributions, showcased by its ranking at #73 out of 208 in Scopus for the latter category. The journal's scope encompasses various aspects of diagnostic pathology, from innovative techniques to critical reviews of pathologic findings, making it an essential resource for researchers, medical professionals, and students dedicated to enhancing diagnostic accuracy and patient care. Although it does not currently offer open access options, its wide readership and impactful publications continue to influence clinical practices and research agendas. With a convergence period extending to 2024, Annals of Diagnostic Pathology remains a leading platform for disseminating valuable knowledge in this dynamic field.